Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

This study demonstrated that genetically engineered, ATP-responsive nanozymes effectively reduce cardiac fibrosis by targeting activated cardiac fibroblasts, resulting in decreased myofibroblast accumulation and improved cardiac function, suggesting that this approach has significant potential for therapeutic applications.

In this nonrandomized controlled trial, tenon capsule injection of platelet-rich plasma improved capillary perfusion and may enhance short-term vision in patients with acute nonarteritic anterior ischemic optic neuropathy.

This study found that nanocapsules formulated as a dispersion and applied with massage may enhance follicular uptake of clobetasol propionate while minimizing its skin penetration, offering a potential improvement over conventional treatments for scalp diseases.

This study found that a 12-week topical treatment with a caffeine and Procapil 3% formulation effectively reduced hair loss by 26.9% and improved hair growth in men with androgenetic alopecia, without any reported adverse effects.

In this study, tacrolimus was as effective as clobetasol propionate in treating alopecia areata, suggesting it can serve as an alternative therapy option.

This review discusses the mechanisms of platinum-induced peripheral neuropathy related to reactive oxygen species and explores potential antioxidant therapies and nanotechnology approaches, but reports no new clinical results.

This study validated that six out of seven tested topical formulations for alopecia are compatible for 6-month use, suggesting they may be practical for compounding pharmacies.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study observed that porocarcinoma exhibited a relatively low rate of local recurrence, nodal metastases, and mortality over a follow-up period exceeding five years.

This study found that retinol palmitate treatment in patients with stage Ia non-small-cell lung cancer may reduce cancer relapses, but longer follow-up is needed to confirm its efficacy.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study reports that Cur@CMCTS-Tk hydrogel effectively accelerated wound healing and tissue regeneration in rats by scavenging excess reactive oxygen species and protecting human fibroblasts from oxidative damage.

This review critically evaluates the evidence for SARMs' tissue selectivity and suggests their clinical benefits over traditional androgens are not yet well-supported by robust evidence, underscoring the need for further head-to-head trials.

This study found that P144 (Disitertide) significantly reduced collagen deposition and improved muscle organization in a rabbit model of post-radiotherapy fibrosis, suggesting potential antifibrotic effects.

This study found that encapsulating latanoprost in nanotransfersomes increased skin penetration and improved its cell proliferation effect in vitro, suggesting potential for treating hair growth disorders.

In this study, researchers investigated the role of the ATX-LPA axis in asthma pathogenesis using human and mouse models and highlighted the potential for developing new ATX inhibitors as effective asthma treatments.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

This study reported that a solid lipid nanoparticle-based gel formulation, specifically optimized for psoriasis, improved drug loading capacity and release properties using high-pressure homogenization, suggesting its potential efficacy as a topical treatment.

This entry contains only a placeholder abstract with no research findings described or summarized.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

This study using a mouse model reports that CuATSM treatment accelerates skin wound healing and reduces scar formation, with effects possibly mediated via the ferroptosis-induced Hippo/YAP signaling pathway and macrophage polarization, suggesting CuATSM as a potential therapy for scarless wound healing in clinical settings.

This study found that Brigatinib-loaded nanospanlastics demonstrated enhanced cytotoxicity against lung cancer cells and improved drug stability and release compared to free Brigatinib.

This study found that tofacitinib was an effective and better-tolerated treatment for moderate-to-severe AA compared to SCs, though its efficacy decreased in patients with disease episodes longer than two years.

This study suggests that in an ex vivo rat glaucoma model, TSPO activation is involved in Allopregnanolone synthesis and may help prevent retinal damage, with TSPO agonists as potential therapeutic agents.

This review discusses the evolution of platelet concentrates in regenerative medicine, highlighting a proposed function-driven classification that distinguishes three generations of PCs by biological activity rather than development order, with third-generation exosome-based therapies showing superior therapeutic efficacy over earlier formulations.